Repositorio Dspace

A New Gain-of-Function NLRP1 Variant Is Associated with Inflammasome Activation and Disease Severity in SLC25A38 Congenital Sideroblastic Anemia Case Report

Mostrar el registro sencillo del ítem

dc.contributor.author Sánchez-Villalobos, María
dc.contributor.author Campos-Baños, Eulalia
dc.contributor.author Martínez-Balsalobre, Elena
dc.contributor.author Pinilla-Marquínez, Miriam
dc.contributor.author Navarro-Ramírez, Verónica
dc.contributor.author Macartney, Thomas
dc.contributor.author Hurtado-Navarro, Laura
dc.contributor.author Hernández-García, David
dc.contributor.author Blanquer-Blanquer, Miguel
dc.contributor.author Pelegrín, Pablo
dc.contributor.author Salido-Fiérrez, Eduardo-José
dc.contributor.author Pérez-Oliva, Ana-Belén
dc.date.accessioned 2026-11-11T09:07:14Z
dc.date.available 2026-11-11T09:07:14Z
dc.date.issued 2026-09-15
dc.identifier.citation Sánchez-Villalobos M, Baños EC, Martínez-Balsalobre E, Pinilla-Marquínez M, Navarro-Ramírez V, Macartney T, et al. A New Gain-of-Function NLRP1 Variant Is Associated with Inflammasome Activation and Disease Severity in SLC25A38 Congenital Sideroblastic Anemia Case Report. J Pers Med. 15 de septiembre de 2026;16(9):471. doi:10.3390/jpm16090471
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29196
dc.description.abstract Inflammasomes play a pivotal role in inflammation and infection, but the clinical relevance of inflammasomes goes beyond infectious disease. Here, we report a novel variant in the NLRP1 gene (p.V939M) identified in a patient with congenital sideroblastic anemia due to a homozygous SLC25A38 mutation. This patient exhibits severe anemia, iron overload, and dependence on frequent transfusions. Functional characterization of peripheral blood mononuclear cells from the patient revealed constitutive activation of the NLRP1 inflammasome in primary cells, evidenced by increased processing of NLRP1, cleavage of CASP1, and ASC oligomerization. Moreover, in a speck in vitro assay, the newly identified genetic variant increases ASC oligomerization, and using ex vivo erythroid differentiation assays with patient-derived cells, we demonstrated that pharmacological inhibition of CASP1 enhances erythrocyte formation. This patient-derived NLRP1 variant was evaluated in a newly generated human NLRP1 knockdown system using CRISPR-Cas9 in K562 cells, in combination with ferroptotic/oxidative stress induction to mimic patient clinical features, and our results indicate that the presence of NLRP1 p.V939M, together with enhanced ferroptosis, may contribute to the patient's phenotype. Furthermore, both CASP1 inhibition and ferroptosis inhibition further enhance the restoration of erythroid colony formation from primary progenitor cells derived from the patient. Therefore, our study identifies a novel NLRP1 inflammasome variant involved in human erythropoiesis and highlights its possible contribution to the pathogenesis of congenital sideroblastic anemia, providing a basis for the development of new potential therapeutic strategies.
dc.language.iso eng
dc.publisher MDPI AG
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es *
dc.title A New Gain-of-Function NLRP1 Variant Is Associated with Inflammasome Activation and Disease Severity in SLC25A38 Congenital Sideroblastic Anemia Case Report
dc.type info:eu-repo/semantics/article
dc.relation.publisherversion https://www.mdpi.com/2075-4426/16/9/471
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.3390/jpm16090471
dc.journal.title Journal of Personalized Medicine
dc.identifier.essn 2075-4426


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta